摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1R,2S,5S)-(6,6-dimethyl-3-azabicyclo[3.1.0]hex-2-yl)methanol | 394734-84-0

中文名称
——
中文别名
——
英文名称
(1R,2S,5S)-(6,6-dimethyl-3-azabicyclo[3.1.0]hex-2-yl)methanol
英文别名
(1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-methanol;[(1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]methanol
(1R,2S,5S)-(6,6-dimethyl-3-azabicyclo[3.1.0]hex-2-yl)methanol化学式
CAS
394734-84-0
化学式
C8H15NO
mdl
——
分子量
141.213
InChiKey
XYHWQEDJUAJEAU-XVMARJQXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    209.3±13.0 °C(Predicted)
  • 密度:
    1.005±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    32.3
  • 氢给体数:
    2
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (1R,2S,5S)-(6,6-dimethyl-3-azabicyclo[3.1.0]hex-2-yl)methanolchromium(VI) oxide硫酸N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下, 以 乙腈 为溶剂, 反应 3.0h, 生成 3-(2-(S)-cyclohexyl-2-isobutoxycarbonylaminoacetyl)-1-(R),5-(S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-(S)-carboxylic acid
    参考文献:
    名称:
    Discovery of SCH446211 (SCH6):  A New Ketoamide Inhibitor of the HCV NS3 Serine Protease and HCV Subgenomic RNA Replication
    摘要:
    Introduction of various modified prolines at P-2 and optimization of the P-1 side chain led to the discovery of SCH6 (24, Table 2), a potent ketoamide inhibitor of the HCV NS3 serine protease. In addition to excellent enzyme potency (K-i* = 3.8 nM), 24 was also found to be a potent inhibitor of HCV subgenomic RNA replication with IC50 and IC90 of 40 and 100 nM, respectively. Recently, antiviral activity of 24 was demonstrated with inhibition of the full-length genotype 2a HCV genome. In addition, 24 was found to restore the responsiveness of the interferon regulatory factor 3 (IRF-3) in cells containing HCV RNA replicons.
    DOI:
    10.1021/jm060077j
  • 作为产物:
    描述:
    (1R,2S,5S)-6,6-二甲基-3-氮杂双环[3.1.0]己烷-2-羧酸甲酯 在 lithium aluminium tetrahydride 作用下, 以 四氢呋喃 为溶剂, 反应 12.0h, 以85%的产率得到(1R,2S,5S)-(6,6-dimethyl-3-azabicyclo[3.1.0]hex-2-yl)methanol
    参考文献:
    名称:
    [EN] PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS
    [FR] PYRAZOLOPYRIMIDINES TENANT LIEU D'INHIBITEURS DE KINASES DEPENDANTES DE LA CYCLINE
    摘要:
    在其多种实施方式中,本发明提供了一类新型的吡唑并[1,5-a]嘧啶化合物,作为细胞周期依赖性激酶的抑制剂,以及制备这类化合物的方法,含有一种或多种这类化合物的药物组合物,制备包含一种或多种这类化合物的药物配方的方法,以及利用这类化合物或药物组合物治疗、预防、抑制或改善与CDKs相关的一种或多种疾病的方法。
    公开号:
    WO2004022561A1
点击查看最新优质反应信息

文献信息

  • [EN] CYCLOBUTENEDIONE GROUPS-CONTAINING COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE<br/>[FR] GROUPES CYCLOBUTENEDIONE CONTENANT DES COMPOSES SERVANT D'INHIBITEURS A LA SERINE PROTEASE NS3 DU VIRUS DE L'HEPATITE C
    申请人:SCHERING CORP
    公开号:WO2005085197A1
    公开(公告)日:2005-09-15
    The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    本发明公开了具有HCV蛋白酶抑制活性的新化合物,以及制备这种化合物的方法。在另一实施方式中,本发明公开了包含这种化合物的药物组合物,以及使用它们治疗与HCV蛋白酶相关的疾病的方法。
  • Syntheses of dipeptides containing (1R,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxylic acid (4), (1R,5S)-spiro[3-azabicyclo[3.1.0]hexane-6,1′-cyclopropane]- 2(S)-carboxylic acid (5) and (1S,5R)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxylic acid (6)
    作者:Siska Hendrata、Frank Bennett、Yuhua Huang、Mousumi Sannigrahi、Patrick A. Pinto、Tze-Ming Chan、C. Anderson Evans、Rebecca Osterman、Alexei Buevich、Andrew.T. McPhail
    DOI:10.1016/j.tetlet.2006.06.052
    日期:2006.9
    Versatile syntheses of dipeptides that incorporate the 3-azabicyclo[3.1.0]hexane system are described.
    描述了结合了3-氮杂双环[3.1.0]己烷系统的二肽的多功能合成方法。
  • [EN] NOVEL BETULINIC SUBSTITUTED AMIDE DERIVATIVES AS HIV INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS D'AMIDE SUBSTITUÉS BÉTULINIQUES UTILISÉS COMME INHIBITEURS DU VIH
    申请人:HETERO RESEARCH FOUNDATION
    公开号:WO2017017630A1
    公开(公告)日:2017-02-02
    The present invention relates to novel betulinic substituted amide compounds of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y, Z1, Z2, Z3 and are Formula (II) as defined herein. The invention novel betulinic substituted amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.
    本发明涉及新的取代苦杏仁酸酰胺化合物的化学式(I);以及其药用盐,其中R1、R2、R3、R4、R5、R6、R7、R8、X、Y、Z1、Z2、Z3和在此定义的化学式(II)。该发明涉及新的取代苦杏仁酸酰胺衍生物、相关化合物和药物组合物,用于治疗病毒性疾病,特别是HIV介导的疾病。
  • Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
    申请人:Saksena K. Anil
    公开号:US20070032433A1
    公开(公告)日:2007-02-08
    The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    本发明揭示了具有HCV蛋白酶抑制活性的新化合物,以及制备这些化合物的方法。在另一种实施方式中,本发明揭示了包含这些化合物的药物组合物,以及使用它们治疗与HCV蛋白酶相关的疾病的方法。
  • Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
    申请人:Guzi J. Timothy
    公开号:US20070281951A1
    公开(公告)日:2007-12-06
    In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or compositions.
    在其许多实施例中,本发明提供了一种新型的嘧唑并[1,5-a]嘧啶类化合物作为细胞周期依赖性激酶抑制剂,制备这种化合物的方法,含有一种或多种此类化合物的组合物,制备包含一种或多种此类化合物的制药配方的方法,并使用这种化合物或组合物进行一种或多种与CDK相关的疾病的治疗、预防、抑制或改善的方法。
查看更多